UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.
The company said headline results from trials involving a total of 400 patients with a pelvic mass studies show the potential for Parsortix to discriminate between benign and malignant pelvic tumours with a degree of sensitivity, having correctly identifyied cancer in up to 95 percent of cases whilst achieving a higher specificity (low false positive rate) than existing tests